CN112423741A - 葡萄糖反应性胰岛素 - Google Patents

葡萄糖反应性胰岛素 Download PDF

Info

Publication number
CN112423741A
CN112423741A CN201980031925.3A CN201980031925A CN112423741A CN 112423741 A CN112423741 A CN 112423741A CN 201980031925 A CN201980031925 A CN 201980031925A CN 112423741 A CN112423741 A CN 112423741A
Authority
CN
China
Prior art keywords
peptide
insulin
chain
group
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980031925.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·H-C·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CN112423741A publication Critical patent/CN112423741A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980031925.3A 2018-04-16 2019-04-15 葡萄糖反应性胰岛素 Pending CN112423741A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658372P 2018-04-16 2018-04-16
US62/658,372 2018-04-16
PCT/US2019/027484 WO2019204206A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Publications (1)

Publication Number Publication Date
CN112423741A true CN112423741A (zh) 2021-02-26

Family

ID=68239869

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980031925.3A Pending CN112423741A (zh) 2018-04-16 2019-04-15 葡萄糖反应性胰岛素

Country Status (8)

Country Link
US (1) US20210214412A1 (enExample)
EP (1) EP3781147A4 (enExample)
JP (1) JP2021521230A (enExample)
KR (1) KR20210005630A (enExample)
CN (1) CN112423741A (enExample)
AU (1) AU2019255611A1 (enExample)
CA (1) CA3097359A1 (enExample)
WO (1) WO2019204206A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
EP3707145B1 (en) 2017-11-09 2023-06-21 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP7640462B2 (ja) * 2019-03-29 2025-03-05 ノヴォ ノルディスク アー／エス グルコース感受性インスリン誘導体
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CA3173417A1 (en) * 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
PH12023500012A1 (en) * 2020-11-19 2024-03-11 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
CN119136821A (zh) * 2022-02-17 2024-12-13 雷沃洛生物医疗有限公司 产生衍生自伴侣蛋白60.1的肽的方法
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
WO2025117822A1 (en) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656722A (en) * 1988-11-08 1997-08-12 Hoechst Aktiengesellschaft A21 -, B30 - modified insulin derivatives having an altered action profile
US20130085101A1 (en) * 2010-02-22 2013-04-04 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
CN103596595A (zh) * 2011-06-02 2014-02-19 韩美科学株式会社 用于治疗糖尿病的包括长效胰岛素缀合物和长效促胰岛素肽缀合物的组合物
CN104428314A (zh) * 2012-04-20 2015-03-18 克列奥梅尼斯·K·巴罗斯 使用侧链锚接赖氨酸的胰岛素的固相肽合成
US20150320837A1 (en) * 2012-12-12 2015-11-12 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070100A (ja) * 1983-09-26 1985-04-20 Wako Pure Chem Ind Ltd 新規ヒト型インシュリン誘導体，その製法，及びヒト型インシュリンの製造法
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
EP3291828A4 (en) * 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656722A (en) * 1988-11-08 1997-08-12 Hoechst Aktiengesellschaft A21 -, B30 - modified insulin derivatives having an altered action profile
US20130085101A1 (en) * 2010-02-22 2013-04-04 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
CN103596595A (zh) * 2011-06-02 2014-02-19 韩美科学株式会社 用于治疗糖尿病的包括长效胰岛素缀合物和长效促胰岛素肽缀合物的组合物
CN104428314A (zh) * 2012-04-20 2015-03-18 克列奥梅尼斯·K·巴罗斯 使用侧链锚接赖氨酸的胰岛素的固相肽合成
US20150320837A1 (en) * 2012-12-12 2015-11-12 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment

Also Published As

Publication number Publication date
EP3781147A1 (en) 2021-02-24
US20210214412A1 (en) 2021-07-15
WO2019204206A1 (en) 2019-10-24
JP2021521230A (ja) 2021-08-26
KR20210005630A (ko) 2021-01-14
EP3781147A4 (en) 2022-04-20
CA3097359A1 (en) 2019-10-24
AU2019255611A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
KR20210005630A (ko) 글루코스-반응성 인슐린
JP7858549B2 (ja) Ｇｌｐ－１とｇｉｐ受容体二重アゴニスト化合物及びその応用
JP6581606B2 (ja) 選択的グルカゴン受容体アゴニストとしてのエキセンジン−４誘導体
EP2694095B1 (en) Compositions comprising glucagon analogs and methods of making and using the same
EP4442700A1 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
US11155577B2 (en) Thiol-ene based peptide stapling and uses thereof
JP6665349B2 (ja) アシル化インスリン化合物
TW202039438A (zh) 胰島素接合物
JP2024546026A (ja) Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用
US20210177981A1 (en) Conjugate based systems for controlled insulin delivery
EP4545086A1 (en) Incretin analog and use thereof
CN117337299A (zh) 葡萄糖响应性胰岛素类似物葡萄糖传感器的分子设计
US11034720B2 (en) Thiol-yne based peptide stapling and uses thereof
CN106554404A (zh) 一种艾塞那肽修饰物及其用途
WO2025016303A1 (zh) Glp-1、gip和gcg受体三激动剂及其应用
JP6005732B2 (ja) 非ペプチド性重合体−インスリン多量体及びその製造方法
EP4357358A1 (en) Glucagon analog and medical use thereof
CN107365375B (zh) 一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
CN116917297A (zh) 芳香族含硼化合物和胰岛素类似物
CN122029186A (zh) 人生长激素受体拮抗剂及其使用方法
TW202608907A (zh) 肽類似物及使用其之方法
BR112019021668B1 (pt) Composto acilado de insulina, uso do mesmo, e composição farmacêutica que o compreende
HK40069563B (zh) Glp-1和gip受体双重激动剂化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210226